Head-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) versus Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) and Protalix BioTherapeutics (NYSE:PLX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Volatility & Risk

Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.

Valuation and Earnings

This table compares Gilead Sciences and Protalix BioTherapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44 billion	6.37	$8.51 billion	($2.67)	-56.69
Protalix BioTherapeutics	$80.62 million	2.80	$8.31 million	$0.23	12.17

Gilead Sciences has higher revenue and earnings than Protalix BioTherapeutics. Gilead Sciences is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Analyst Recommendations

This is a summary of current recommendations and price targets for Gilead Sciences and Protalix BioTherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0	5	23	1	2.86
Protalix BioTherapeutics	0	0	1	0	3.00

Gilead Sciences currently has a consensus price target of $158.78, indicating a potential upside of 4.89%. Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 328.57%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Gilead Sciences.

Summary

Gilead Sciences beats Protalix BioTherapeutics on 10 of the 15 factors compared between the two stocks.

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.